Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 4/20 | 0.61 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.61 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.61 |
| ▸ | ABAT | P80404 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.61 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.56 |
| ▸ | FDPS | P14324 | 1/20 | 0.53 |
| ▸ | TTR | P02766 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2558253 | 0.87 | ALDH1A1 (0.53) | CYP2C9NPC1RAB9ANPSR1ALDH1A1 | |
| SCHEMBL29956561 | 0.86 | ALDH1A1 (0.61) | CYP2C9NPC1RAB9ANPSR1ALDH1A1 | |
| SCHEMBL7033712 | 0.86 | ALDH1A1 (0.61) | CYP2C9NPC1RAB9ANPSR1ALDH1A1 | |
| SCHEMBL2934800 | 0.86 | ALDH1A1 (0.61) | CYP2C9NPC1RAB9ANPSR1ALDH1A1 | |
| SCHEMBL10415024 | 0.84 | ALDH1A1 (0.59) | CYP2C9NPC1RAB9ANPSR1ALDH1A1 | |
| SCHEMBL15652453 | 0.84 | ALDH1A1 (0.65) | CYP2C9NPC1RAB9ANPSR1ALDH1A1 | |
| SCHEMBL359439 | 0.84 | ALDH1A1 (0.63) | CYP2C9NPC1RAB9ANPSR1ALDH1A1 | |
| SCHEMBL2558096 | 0.83 | TRIM24 (0.57) | CYP2C9NPC1RAB9ANPSR1ALDH1A1 | |
| SCHEMBL8128040 | 0.83 | ALDH1A1 (0.56) | CYP2C9NPC1RAB9ANPSR1ALDH1A1 | |
| SCHEMBL11653267 | 0.83 | CYP2C9 (0.56) | CYP2C9NPC1RAB9ANPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4168399-B1 | COMPOUNDS AND THEIR USES AS MIF INHIBITORS | NANJING IMMUNOPHAGE BIOMEDICAL CO LTD (CN) | 2026-04-01 | — | — | EP | disclosed |
| US-20240083912-A1 | COMPOUNDS AND THEIR USES AS MIF INHIBITORS | NANJING IMMUNOPHAGE BIOTECH CO LTD (CN) | 2024-03-14 | — | — | US | disclosed |
| US-11884682-B2 | Compounds and their uses as MIF inhibitors | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2024-01-30 | — | — | US | disclosed |
| CN-116438174-A | Compounds and their use as MIF inhibitors | 南京艾美斐生物医药科技有限公司 | 2023-07-14 | — | — | CN | disclosed |
| EP-4168399-A1 | COMPOUNDS AND THEIR USES AS MIF INHIBITORS | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2023-04-26 | — | — | EP | disclosed |
| WO-2021258272-A1 | COMPOUNDS AND THEIR USES AS MIF INHIBITORS | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2021-12-30 | — | — | WO | disclosed |
| US-20210403484-A1 | COMPOUNDS AND THEIR USES AS MIF INHIBITORS | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2021-12-30 | — | — | US | disclosed |
| EP-3150643-B1 | TRIPHENYLMETHANE-BASED COLORED COMPOSITION | WAKO PURE CHEM IND LTD (JP) | 2017-12-27 | — | — | EP | disclosed |
| US-20170190818-A1 | TRIPHENYLMETHANE-BASED COLORED COMPOSITION | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
| US-20170190818-A1 | TRIPHENYLMETHANE-BASED COLORED COMPOSITION | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
| US-6083961-A | FOR PREVENTION AND/OR TREATMENT OF BRADYKININ OR ITS ANALOGUES MEDIATED DISEASES SUCH AS ALLERGY, INFLAMMATION, AUTOIMMUNE DISEASE, SHOCK, PAIN | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-04 | — | — | US | disclosed |
| US-6015818-A | TREATING KIDNEY, BRAIN, AND CARDIOVASCULAR DISORDERS; HYPOTENSIVE AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-01-18 | — | — | US | disclosed |
| US-5849796-A | Ortho-substituted benzoil acid derivatives | MERCK PATENT GELSELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1998-12-15 | — | — | US | disclosed |
| EP-0879233-A1 | CHINOLINE AND BENZIMIDAZOLE DERIVATIVES AS BRADYKININ AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-11-25 | — | — | EP | disclosed |
| WO-1997028153-A1 | CHINOLINE AND BENZIMIDAZOLE DERIVATIVES AS BRADYKININ AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-07 | — | — | WO | disclosed |
| EP-0774462-A1 | HETEROCYCLIC COMPOUND | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-21 | — | — | EP | disclosed |
| EP-0704431-A2 | Ortho-substituted benzoic acid derivatives | MERCK PATENT GmbH (DE) | 1996-04-03 | — | — | EP | disclosed |
| US-4184977-A | WHITENING | BAYER AKTIENGESELLSCHAFT (DE) | 1980-01-22 | — | — | US | disclosed |
| EP-0000346-B1 | QUINOXALINE COMPOUNDS, PROCESS FOR THEIR MANUFACTURE AND THEIR USE AS BRIGHTENERS FOR ORGANIC MATERIALS, AND THE MATERIALS BRIGHTENED THEREWITH | BAYER AG (DE) | 1980-01-09 | — | — | EP | disclosed |
| EP-0000346-A1 | Quinoxaline compounds, process for their manufacture and their use as brighteners for organic materials, and the materials brightened therewith | BAYER AG (DE) | 1979-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11884682-B2 | Compounds and their uses as MIF inhibitors | MIF, CCL11, CCL2 | CYP2C9 2049/4885NPC1 255/4885RAB9A 3018/4885 |
| US-20240083912-A1 | COMPOUNDS AND THEIR USES AS MIF INHIBITORS | MIF, CCL11, CCL2 | CYP2C9 2049/4885NPC1 255/4885RAB9A 3018/4885 |
| US-20210403484-A1 | COMPOUNDS AND THEIR USES AS MIF INHIBITORS | MIF, CCL11, CCL2 | CYP2C9 2049/4885NPC1 255/4885RAB9A 3018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.